Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023
Aravive, Inc. announced that its CEO, Gail McIntyre, will be participating in a fireside chat at the William Blair Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success on July 18, 2023. The event will be held virtually and a replay will be available for 7 days.
07/14/2023 - 07:05 AM
HOUSTON, July 14, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer will be participating in a fireside chat at the William Blair Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success being held virtually on July 18, 2023.
William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Format: Fireside Chat with Aravive (ARAV) Date/Time: Tuesday, July 18, 2023 at 12:00-12:45 PM ET Host: Andy Hsieh, Ph.D., Biotech Research Analyst, William Blair Presenter: Gail McIntyre, Ph.D., DABT, CEO, Aravive Webcast: Conference attendees can check the schedule for more details or reach out to their William Blair salesperson.
A replay of the session will be available for 7 days following the event through the Aravive Events & Presentations section of the website https://ir.aravive.com/events-and-presentations .
About Aravive Aravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease. Our lead product candidate, batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the U.S. FDA and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase 3 trial in platinum resistant ovarian cancer (NCT04729608), a Phase 1b/2 trial in clear cell renal cell carcinoma (NCT04300140), and a Phase 1b/2 trial in pancreatic adenocarcinoma (NCT04983407). The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. Additional information at www.aravive.com .
Investor Relations Contact: Corey Davis, Ph.D. LifeSci Advisors, LLC 212-915-2577cdavis@lifesciadvisors.com
Gail McIntyre, Ph.D., DABT, the CEO of Aravive, Inc.
The event will be held virtually on July 18, 2023.
Yes, a replay of the session will be available for 7 days following the event.
The replay will be available through the Aravive Events & Presentations section of their website.
ARAV Rankings
N/A Ranked by Stock Gains
ARAV Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Houston
About ARAV
versartis, inc. (nasdaq: vsar) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. the company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. versartis’ mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. learn more at www.versartis.com.